APA (7th ed.) Citation

Hagege, O., Lequerre, T., Marcelli, C., Varin, R., Alcaix, D., Weber, A. J., . . . Vittecoq, O. (2023). AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY). Annals of the rheumatic diseases, 82(Suppl 1), 2042. https://doi.org/10.1136/annrheumdis-2023-eular.4416

Chicago Style (17th ed.) Citation

Hagege, O., T. Lequerre, C. Marcelli, R. Varin, D. Alcaix, A. J. Weber, S. D. Mihailescu, E. Duhamel, and O. Vittecoq. "AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY)." Annals of the Rheumatic Diseases 82, no. Suppl 1 (2023): 2042. https://doi.org/10.1136/annrheumdis-2023-eular.4416.

MLA (9th ed.) Citation

Hagege, O., et al. "AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY)." Annals of the Rheumatic Diseases, vol. 82, no. Suppl 1, 2023, p. 2042, https://doi.org/10.1136/annrheumdis-2023-eular.4416.